Gilead Acquisition Of Corus Adds Respiratory Disease Candidate

Gilead exercised an option to buy the maker of the investigational inhaled antibiotic Cayston for $365 mil.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet